eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

European patent for modified aptamers (PB012 PureApta)

9 February

2021

European patent for modified aptamers (PB012 PureApta)

The European Patent Office issued a decision on granting a European patent for PureApta elements.

Pure Biologics’ publication in the Journal of Biomedical Science

28 January

2021

Pure Biologics’ publication in the Journal of Biomedical Science

Klaus, T., Deshmukh, S. pH-responsive antibodies for therapeutic applications. J Biomed Sci 28, 11 (2021)

PB012 PureApta on the NCBR beneficiaries’ list of successes

12 January

2021

PB012 PureApta on the NCBR beneficiaries’ list of successes

The National Center for Research and Development placed the project on the list of beneficiaries' successes.

PB001 project – the first pre-clinical panel is underway

8 January

2021

PB001 project – the first pre-clinical panel is underway

The research is carried out by Timeline Bioresearch, experienced in immuno-oncology and intestinal cancer models.

Pure Biologics debut on the WSE Main Market – news

16 December

2020

Pure Biologics debut on the WSE Main Market – news

News on the debut of Pure Biologics on the WSE Main Market in key business and industry media.

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

18 December

2023

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

23 November

2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020